Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 9,958 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: MATCH Clear all
Completed Phase 2 Interventional Results available

Effort to Prevent Nosocomial Pneumonia Caused by Pseudomonas Aeruginosa in Mechanically Ventilated Subjects

NCT02696902
View directory record Official record
Conditions
Pseudomonas Aeruginosa
Interventions
MEDI3902, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
Englewood, Colorado • Gainesville, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Pharmacokinetics, and Tolerability of ABI-1179 in Healthy Subjects and in Subjects Seropositive for HSV-2 With Recurrent Genital Herpes

NCT06698575
View directory record Official record
Conditions
Recurrent Genital Herpes Simplex Type 2
Interventions
ABI-1179, ABI-1179 Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
4
States / cities
Kansas City, Missouri • Rochester, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Sodium Bicarbonate Supplementation in Chronic Kidney Disease Evaluation of Dose Response, Safety and Beneficial Effects

NCT00888290
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Placebos
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Not applicable Interventional

Anxiety Sensitivity Treatment to Reduce Anxiety in Alzheimer's

NCT05748613
View directory record Official record
Conditions
Anxiety, Mild Cognitive Impairment, Alzheimer Disease, Dementia
Interventions
Computerized Anxiety Sensitivity Treatment, Health Education Control
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
60 Years and older
Enrollment
388 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
3
States / cities
Tallahassee, Florida • Athens, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Study to Treat Major Depressive Disorder With a New Medication

NCT03043560
View directory record Official record
Conditions
Depressive Disorder, Anhedonia
Interventions
Ezogabine, Placebos
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 65 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Reading Outcomes in Children With Vestibular Loss

NCT05414903
View directory record Official record
Conditions
Vestibular Disorder, Hearing Loss, Sensorineural
Interventions
Dynamic Visual Acuity, Reading Outcomes, Static Visual Acuity
Behavioral
Lead sponsor
Father Flanagan's Boys' Home
Other
Eligibility
7 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder

NCT07767903
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
SEP-363856, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
384 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
11
States / cities
Redlands, California • Orlando, Florida • Watertown, Massachusetts + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy

NCT00609466
View directory record Official record
Conditions
Bunionectomy, Pain, Postoperative Pain, Acute Pain
Interventions
CG5503 IR, Morphine, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years to 80 Years
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
6
States / cities
Pasadena, Maryland • Austin, Texas • Houston, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Atogepant for Prophylaxis of Migraine in Participants Who Failed Previous Oral Prophylactic Treatments.

NCT04740827
View directory record Official record
Conditions
Episodic Migraine
Interventions
Atogepant 60 mg, Placebo
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 80 Years
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
26
States / cities
Colton, California • Encino, California • Los Alamitos, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Maribavir Administered in Healthy Japanese Participants Compared With Matched, Healthy, Non-Hispanic, Caucasian Participants and to Assess Dose-Proportionality of 3 Doses of Maribavir in Japanese Participants

NCT04497883
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir (400 mg), Maribavir (200 mg), Maribavir (800 mg)
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-079 in People With Generalized Myasthenia Gravis

NCT04159805
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
TAK-079, TAK-079 Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
27
States / cities
Tucson, Arizona • Palo Alto, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 21, 2026, 7:35 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Neurovascular Complications and White Matter Damage in Acquired Anemias

NCT04320966
View directory record Official record
Conditions
Anemia, Iron-deficiency Anemia, Healthy Controls
Interventions
Not listed
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
16 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
4
States / cities
Duarte, California • Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies

NCT02743351
View directory record Official record
Conditions
Hematologic Malignancies, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Acute Graft-versus-host Disease
Interventions
ProTmune, Control Arm
Biological
Lead sponsor
Fate Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
15
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 21, 2026, 7:35 AM EDT
Terminated Phase 2 Interventional Results available

Effects of ABT-089 on Smoking Abstinence Symptoms and Reward

NCT01756053
View directory record Official record
Conditions
Nicotine Addiction
Interventions
ABT-089, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 29, 2014 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment

NCT05318937
View directory record Official record
Conditions
Parkinson Disease, Cognitive Dysfunction
Interventions
SAGE-718-matching placebo, SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 75 Years
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
38
States / cities
Sun City, Arizona • Little Rock, Arkansas • Fresno, California + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Early Phase 1 Interventional

Confirmatory Efficacy Trial of Attention Bias Modification for Depression

NCT06361095
View directory record Official record
Conditions
Depression
Interventions
Traditional Attention Bias Modification, Gamified Attention Bias Modification, Sham Attention Bias Modification
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 70 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 3 Interventional

NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

NCT06911112
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
NBI-1065845, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
17
States / cities
Huntsville, Alabama • Bryant, Arkansas • Glendale, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-human, Safety, Tolerability, and Pharmacokinetics Study of LXE408 in Healthy Subjects

NCT07809919
View directory record Official record
Conditions
Visceral Leishmaniasis, Chagas Disease
Interventions
LXE408, Placebo, Iohexol
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Not yet recruiting Not applicable Interventional

Knotless Versus Conventional Sutures for Wound Closure in Cerebral Palsy Multilevel Surgery

NCT07880197
View directory record Official record
Conditions
Cerebral Palsy
Interventions
Knotless barbed suture, Conventional suture
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF)

NCT06264310
View directory record Official record
Conditions
Heart Failure, Worsening Heart Failure (WHF)
Interventions
Placebo, R2R01
Drug
Lead sponsor
River 2 Renal Corp.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
8
States / cities
Fairhope, Alabama • Fort Meyers, Florida • Hialeah, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 2 Interventional

Study to Evaluate Efficacy and Safety of LIB003 in Patients on Lipid-Lowering Therapy Needing Additional LDL-C Reduction

NCT03549260
View directory record Official record
Conditions
LDL Cholesterol
Interventions
LIB003
Biological
Lead sponsor
LIB Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Indianapolis, Indiana • Louisville, Kentucky • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Oct 21, 2026, 7:35 AM EDT
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

NCT00731120
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Vortioxetine, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
40
States / cities
Birmingham, Alabama • Anaheim, California • Cerritos, California + 37 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 21, 2026, 7:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Study of Single Doses of HBS-104 in Acutely Sleep-deprived Healthy Participants

NCT07848659
View directory record Official record
Conditions
Sleep Deprivation
Interventions
HBS-104, Placebo
Drug
Lead sponsor
Harmony Biosciences Management, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 7:35 AM EDT